Plasma Proteomics of COVID-19 Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics Jason Roh Harvard Medical School Robert Kitchen Harvard Medical School https://orcid.org/0000-0003-1443-8559 J Sawalla Guseh Massachusetts General Hospital Jenna McNeill Massachusetts General Hospital Malika Aid Beth Israel Deaconess Medical Center BIDMC Amanda Martinot Tufts University https://orcid.org/0000-0001-6237-6191 Andy Yu Massachusetts General Hospital Colin Platt Massachusetts General Hospital James Rhee Massachusetts General Hospital Brittany Weber Brigham and Women's Hospital Lena Trager Massachusetts General Hospital Margaret Hastings Massachusetts General Hospital Sarah Ducat Tufts University https://orcid.org/0000-0002-5285-7642 Peng Xia Massachusetts General Hospital Claire Castro Massachusetts General Hospital Bjarni Atlason Page 1/26 Massachusetts General Hospital Timothy Churchill Massachusetts General Hospital Marcelo Di Carli Brigham and Women's Hospital Patrick Ellinor The Broad Institute of MIT and Harvard https://orcid.org/0000-0002-2067-0533 Dan Barouch Beth Israel Deaconess Medical Center https://orcid.org/0000-0001-5127-4659 Jennifer Ho Massachusetts General Hospital Anthony Rosenzweig (
[email protected] ) Massachusetts General Hospital Article Keywords: COVID-19, cardiovascular complications, disease severity, mortality Posted Date: June 8th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-539712/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/26 Abstract Cardiovascular complications are common in COVID-19 and strongly associated with disease severity and mortality. However, the mechanisms driving cardiac injury and failure in COVID-19 are largely unknown. We performed plasma proteomics on 80 COVID-19 patients and controls, grouped according to disease severity and cardiac involvement.